SCHEMBL23121671

SCHEMBL23121671

O=C(c1cccc(-n2ccc(=O)[nH]c2=O)c1)N1CCC(OC2CCNCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 3/20 0.43
▸ CHRM1 P11229 2/20 0.42
▸ GABRD O14764 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRB1 P18505 1/20 0.42
▸ GABRA5 P31644 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ GABRA2 P47869 1/20 0.42
▸ GABRB2 P47870 1/20 0.42
▸ GABRA4 P48169 1/20 0.42
▸ BCL9 O00512 2/20 0.40
▸ CTNNB1 P35222 2/20 0.40
▸ EGFR P00533 2/20 0.39
▸ L3MBTL3 Q96JM7 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23122764 0.99 HSD11B1 (0.42) HSD11B1CHRM1GABRDGABRA1GABRB1
SCHEMBL23121719 0.87 HSD11B1 (0.38) HSD11B1CHRM1BCL9CTNNB1EGFR
Hydrochloric Acid SCHEMBL23121759 0.86 BCL9 (0.38) HSD11B1CHRM1BCL9CTNNB1EGFR
SCHEMBL23120510 0.83 BCL9 (0.40) HSD11B1BCL9CTNNB1L3MBTL3L3MBTL1
SCHEMBL23122017 0.83 HSD11B1 (0.43) HSD11B1GABRDGABRA1GABRB1GABRA5
Hydrochloric Acid SCHEMBL23123755 0.82 BCL9 (0.41) HSD11B1BCL9CTNNB1L3MBTL3L3MBTL1
Hydrochloric Acid SCHEMBL23121686 0.82 HSD11B1 (0.42) HSD11B1GABRDGABRA1GABRB1GABRA5
SCHEMBL23121698 0.81 HSD11B1 (0.44) HSD11B1BCL9CTNNB1L3MBTL1
Hydrochloric Acid SCHEMBL23122710 0.81 HSD11B1 (0.43) HSD11B1BCL9CTNNB1
SCHEMBL23121669 0.78 DDB1 (0.46) HSD11B1GABRDGABRA1GABRB1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-10-06 — — US disclosed
CN-114641473-A BRD9 bifunctional degradation agent and use method thereof 诺华股份有限公司 2022-06-17 — — CN disclosed
WO-2021055295-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE BRD9, BRD2, BRD1 HSD11B1 972/4885CHRM1 3234/4885GABRD 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback